Dr. Hibba Tul Rehman
Claim this profileCentral Vermont Medical Center/National Life Cancer Treatment
Area of expertise
Lung Cancer
Hibba Tul Rehman has run 3 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Hibba Tul Rehman has run 3 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Central Vermont Medical Center/National Life Cancer Treatment
University Of Vermont Medical Center
Clinical Trials Hibba Tul Rehman is currently running
Biomarker-Guided Immunotherapy Discontinuation
for Melanoma
This trial uses drugs that boost the immune system to fight advanced melanoma that can't be surgically removed. It aims to see if doctors can safely shorten the treatment period by using imaging tests to guide decisions. Pembrolizumab and ipilimumab are immunotherapy drugs used to treat advanced melanoma, with pembrolizumab approved for younger patients and ipilimumab showing positive results in previous studies.
Recruiting
1 award
Phase 2
22 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting
1 award
Phase 2 & 3
13 criteria
More about Hibba Tul Rehman
Clinical Trial Related
9 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Hibba Tul Rehman has experience with
- Pembrolizumab
- Nivolumab
- Ipilimumab
- Crizotinib
- Screening Platform
- Gemcitabine Hydrochloride
Breakdown of trials Hibba Tul Rehman has run
Lung Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Hibba Tul Rehman specialize in?
Hibba Tul Rehman focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage I patients, or patients who are Stage II.
Is Hibba Tul Rehman currently recruiting for clinical trials?
Yes, Hibba Tul Rehman is currently recruiting for 2 clinical trials in Berlin Vermont. If you're interested in participating, you should apply.
Are there any treatments that Hibba Tul Rehman has studied deeply?
Yes, Hibba Tul Rehman has studied treatments such as Pembrolizumab, Nivolumab, Ipilimumab.
What is the best way to schedule an appointment with Hibba Tul Rehman?
Apply for one of the trials that Hibba Tul Rehman is conducting.
What is the office address of Hibba Tul Rehman?
The office of Hibba Tul Rehman is located at: Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont 05602 United States. This is the address for their practice at the Central Vermont Medical Center/National Life Cancer Treatment.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.